Immunovant, Inc.

What they do

Immunovant is developing IMVT-1402 (imeroprubart), a fully human monoclonal antibody inhibitor of the neonatal fragment crystallizable receptor (FcRn), intended to reduce total and pathogenic IgG antibodies in autoimmune diseases. Following discontinuation of its first-generation antibody batoclimab in April 2026 after two Phase 3 thyroid eye disease studies missed their primary endpoint, the company's efforts are focused entirely on IMVT-1402. It currently runs ongoing studies in six indications: Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE). The company is majority-owned by Roivant (Nasdaq: ROIV) and has no products approved for commercial sale.

Revenue drivers

• IMVT-1402 (imeroprubart) — future product revenue — Pre-revenue. The company has no approved products; all revenue would come from future approval and commercialization of IMVT-1402. Potentially registrational trials are ongoing in GD, D2T RA, MG, CIDP and SjD, with a proof-of-concept trial in CLE.
• Graves' disease (GD) — The lead indication; management says current cash provides runway to the potential commercial launch of IMVT-1402 in GD. Topline data from the potentially registrational GD trial are anticipated in calendar year 2027.
• Myasthenia gravis (MG) — Potentially registrational IMVT-1402 trial ongoing, with topline data anticipated in calendar year 2027.
• CIDP, Sjögren's disease, D2T RA and CLE — Additional indications with no current revenue. Topline data are expected in calendar year 2028 for the CIDP and SjD potentially registrational trials; updates on the D2T RA program and topline CLE proof-of-concept data are expected in the second half of calendar 2026.

Recent performance

For the fiscal first quarter ended June 30, 2026, Immunovant reported a net loss of $153.2 million ($0.75 per common share), compared with $120.6 million ($0.71 per share) for the same quarter a year earlier. Non-GAAP net loss was $139.4 million versus $102.1 million. R&D expenses rose to $142.6 million from $101.2 million, driven primarily by IMVT-1402 clinical trial activities including contract manufacturing costs, partly offset by winding down batoclimab trials. G&A expenses fell to $17.7 million from $26.0 million on lower personnel-related expenses, professional fees, market research and IT costs. Cash and cash equivalents totaled $797.8 million as of June 30, 2026, with 206,264,878 common shares outstanding.

Strategy

Immunovant's stated strategy is to pursue a broad anti-FcRn program built around IMVT-1402's potential best-in-class profile, prioritizing indications of significant unmet need where it could be first- and best-in-class. It is executing all six current indications first, using the intended commercial drug formulation and delivery device — the YpsoMate autoinjector developed by Ypsomed AG — across all IMVT-1402 studies. The company discontinued batoclimab development in all indications and is applying that program's clinical data, operational trial experience and investigator relationships to IMVT-1402. All IMVT-1402 development timelines remain on track per the company.

Risks

• No approved products or revenue — The company has no products approved for commercial sale and may never develop marketable products, so its business depends entirely on clinical success and regulatory approval of IMVT-1402.
• Clinical and regulatory failure — Two Phase 3 batoclimab trials in thyroid eye disease missed their primary endpoint, leading to discontinuation of batoclimab across all indications, illustrating the risk that IMVT-1402 trials could similarly fail.
• Cash burn and funding needs — Net loss was $153.2 million in the quarter ended June 30, 2026 and operating cash flow was negative $407.3 million for fiscal 2026, requiring continued capital to fund six ongoing clinical programs.
• Dependence on a single asset — After discontinuing batoclimab, the company's entire pipeline rests on IMVT-1402, so any setback in that program would affect the whole business.

Outlook

Management says all IMVT-1402 clinical development timelines remain on track and that the current cash balance provides runway to the potential launch of IMVT-1402 in GD. Further updates on the potentially registrational D2T RA program and topline data from the CLE proof-of-concept trial are expected in the second half of calendar 2026. Topline data are anticipated in calendar 2027 for the potentially registrational GD and MG trials, and in calendar 2028 for the CIDP and SjD trials.